Skip to main content
logo
Spyre Therapeutics, Inc. (SYRE)
NASDAQ: SYRE · Real-Time Price · USD
88.98
+1.73 (1.98%)
Sep 4, 2026, 4:00 PM EDT - Market closed

Spyre Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.

Total Valuation

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Market Capitalization
7,8462,5421,36777528234
Market Cap Growth
681.06%85.99%76.31%2701.10%-88.19%-37.90%
Enterprise Value
6,7002,2121,108959-41127
Last Close Price
88.9832.7623.2821.5211.25118.75

Price Ratios

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PS Ratio
---874.9111.8812.50
PB Ratio
8.213.552.644.210.552.79
P/TBV Ratio
8.224.543.78-0.552.79

EV Ratios

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
EV/Sales Ratio
---1082.03-6.78

Financial Efficiency

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Debt / Equity Ratio
----0.090.07
Net Debt / Equity Ratio
-1.04-1.06-1.16-1.84-1.01-1.04
Net Debt / EBITDA Ratio
--2.902.900.611.37
Net Debt / FCF Ratio
5.484.473.833.400.641.62
Asset Turnover
---0.000.030.14
Quick Ratio
18.2312.9411.1610.613.834.66
Current Ratio
18.5313.2511.2610.684.254.91
Return on Equity (ROE)
-22.98%-25.17%-59.28%-289.17%-124.87%-58.81%
Return on Assets (ROA)
-19.81%-19.80%-27.43%-35.60%-58.53%-30.22%
Return on Capital Employed (ROCE)
-24.50%-30.50%-37.60%-38.00%-150.10%-73.10%

Yields

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Earnings Yield
-1.91%-6.11%-15.22%-43.70%-302.87%-28.09%
FCF Yield
-2.66%-6.66%-11.52%-12.89%-289.74%-23.17%
Buyback Yield / Dilution
-31.80%-36.21%-581.85%-104.59%-28.19%-23.18%
SEC Filings: 10-K · 10-Q